Abstract
The sustained release tablets were formulated by using the combination of various release retardant polymers/excipient. The polymers used were hydroxypropyl methylcellulose, Micro Crystalline Cellulose and Sodium starch glycolate. The present investigation involves formulation and evaluation of sustained release tablets of Valsartan with a view to prolong the drug release in the gastrointestinal tract and consequently into the plasma. It showed good linearity and reproducibility which also indicated the analytical method used in the present study to be suitable for the estimation of the drug candidates in different dissolution media. Evaluation parameters such as thickness and diameter, weight variation and drug content uniformity test. The observation for all above evaluation parameters indicate that the values are within the IP specified limits. Thus, on the basis of our research findings it could be concluded that the performance of the developed sustained release tablets was found to be promising for the treatment of hypertension.
Highlights
IntroductionHigh blood pressure (HBP) or hypertension means high pressure (tension) in the arteries
High blood pressure (HBP) or hypertension means high pressure in the arteries
The present investigation involves formulation and evaluation of sustained release tablets of Valsartan with a view to prolong the drug release in the gastrointestinal tract and into the plasma. It showed good linearity and reproducibility which indicated the analytical method used in the present study to be suitable for the estimation of the drug candidates in different dissolution media
Summary
High blood pressure (HBP) or hypertension means high pressure (tension) in the arteries. Sustained-release dosage forms have been referred to as controlled-, delayed, extended- or modified-release dosage forms These terms describe a dosage form that controls the drug absorption rate to achieve a desired plasma profile defined by steady-state pharmacology, for a particular compound after pre-determined lag times or intervals [1]. Sustained release cardiac products can synchronize drug delivery with circadian rhythms in order to optimize efficacy and/or minimize sideeffects. The emergence of controlled delivery system coordination of medical treatment with biological rhythms is especially useful for disease states with known circadian patterns. By taking advantage of known biological patterns in disease manifestation, the goal of developing sustained release products to optimize the desired effects of a drug and minimize its undesired ones, can be achieved in certain disease states. There is a high incidence of disease symptoms and adverse
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
